Genitourinary Cancer, Bladder Cancer, Renal Cancer Clinical Trial 20193097

[LCID Study Number: 20193097]

A031702: A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

The purpose of this study is to test the good and bad effects of the drugs called cabozantinib, nivolumab and ipilimumab, when given in combination.

Disease/Condition: Genitourinary Cancer, Bladder Cancer, Renal Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

View NCT ID 03866382 on ClinicalTrials.gov
Protocol #: 20193097
Principal Investigator(s): Brendan J. Connell
Trial Phase: Sponsor Initiated Study Phase 2